MedTrace Logo

Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy

NCT01867203 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-03-18

No results posted yet for this study

Summary

Patients needing lipid lowering therapy will be recruited before initiation of the treatment. For each patient, total and LDL cholesterol levels before start of therapy will be measured. One, three and six months after his/her first visit, when steady-state will be reached, for each included patient, the cholesterol levels will be re-assessed in order to evaluate the response to statin therapy calculated as the amplitude of cholesterol reduction. The aim is to assess the association between patient's genotype and the response to statin therapy.

Conditions

  • Patients With High Cholesterol Levels Needing a Lipid-lowering Therapy

Interventions

OTHER

Genotyping

DNA extraction from blood

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2019-08-01
Completion
2019-09-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01867203 on ClinicalTrials.gov